Table 1 Cost-effectiveness model: input variables and sources

Prevalence of MUTYH mutations in population

1.5%

1–2%

Al Tassan 2002, Croituro 2004, own data (unpublished) [1;6]

Prevalence of CRC in MAP patients

60%

40–70%

Nielsen 2005, Sampson 2003, Gismondi 2004 [2–4]

Mean age of diagnosis of CRC in MAP patients

49 year

Nielsen 2005, Sampson 2003, Gismondi 2004 [2–4]

Baseline cure rate in MAP patients after CRC

52%

30–60%

IKA/Association of Comprehensive Cancer Centers, [13]

Mean number of children per family

2 children

40 Dutch MAP patients (own data, unpublished)

Life expectancy after CRC

Table*

IKA/Association of Comprehensive Cancer Centers, [13]

Life expectancy total population

Table*

Central Bureau of Statistics (Statistics Netherlands), [32]

Utility after CRC

0.90

0.85–0.95

[24]- utility 9 month after surgery- mean [22] [23]

Spouses compliance to testing

75%

0–100%

See methods, own data, Rowley 2004 [11]

Childrens' compliance to testing

75%

50–100%

Rowley 2004 [11]

Age start screening children

25 year

20–25 year

See text

CRC costs

50–200%

van den Brink 2004 [24]

• initial treatment and recurrence

21,330

• continuing care

2130/year

• non-health care (productivity)

11,060

Costs of genetic testing in a DNA diagnostic laboratory social costs (travel/production)

645€

95€

200–1000€

Costs genetic testing Leiden University Medical Center (LUMC) [25]

Colonoscopy costs (including polypectomy and complications)

561€ (480€ + 81€)

LUMC, Heitman 2005 [18]

Social costs (travel/production)

70€

Oostenbrink 2004 [25]

Effectiveness colonoscopy (reduction in CRC cases)

90%

70–80%

Winawer 1993 [16]

Effectiveness FOBT (reduction in mortality)

11%

10–30%

Kronborg 2004 [19] Faivre 2004 [20]

FOBT

65€ (18€ medical & 47€ time)

Gyrd-Hansen 1998, Oostenbrink 2004 [7] [25]

Discount rate

4%

3–5%

Oostenbrink 2004 [25]